Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease

TY - JOUR

T1 - Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease

AU - Joyce, V. R.

AU - Barnett, P. G.

AU - Bayoumi, A. M.

AU - Griffin, S. C.

AU - Kyriakides, T. C.

AU - Yu, W.

AU - Sundaram, Vandana

AU - Holodniy, M.

AU - Brown, Sheldon

AU - Cameron, W.

AU - Youle, M.

AU - Sculpher, M.

AU - Anis, A. H.

AU - Owens, D. K.

N1 - Joyce, Vilija R Barnett, Paul G Bayoumi, Ahmed M Griffin, Susan C Kyriakides, Tassos C Yu, Wei Sundaram, Vandana Holodniy, Mark Brown, Sheldon T Cameron, William Youle, Mike Sculpher, Mark Anis, Aslam H Owens, Douglas K Medical Research Council/United Kingdom 1999 J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):27-36.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - OBJECTIVE: To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables. DESIGN: Cross-sectional study. SETTING: Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada, and 8 hospitals in the United Kingdom. PATIENTS: Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial. MEASUREMENTS: Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV), the EQ-5D, the EQ-5D visual analog scale (EQ-5D VAS), the Health Utilities Index Mark 3 (HUI3), and standard gamble (SG) and time trade-off (TTO) techniques. RESULTS: The mean (SD) baseline HRQoL scores were as follows: MOS-HIV physical health summary score 41.70 (11.16), MOS-HIV mental health summary score 44.76 (11.38), EQ-5D 0.77 (0.19), HUI3 0.59 (0.32), EQ-5D VAS 65.94 (21.71), SG 0.75 (0.29), and TTO 0.80 (0.31). Correlations between MOS-HIV summary scores and EQ-5D, EQ-5D VAS, and HUI3 ranged from 0.60 to 0.70; the correlation between EQ-5D and HUI3 was 0.73; and the correlation between SG and TTO was 0.43. Preference-based HRQoL scores were related to physical, mental, social, and overall health as measured by MOS-HIV. Concomitant medication use, CD4 cell count, and HIV viral load were related to some instruments' scores. CONCLUSIONS: On average, preference-based HRQoL for treatment-experienced HIV patients was decreased relative to national norms but also highly variable. Health status and clinical variables were related to HRQoL.

AB - OBJECTIVE: To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables. DESIGN: Cross-sectional study. SETTING: Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada, and 8 hospitals in the United Kingdom. PATIENTS: Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial. MEASUREMENTS: Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV), the EQ-5D, the EQ-5D visual analog scale (EQ-5D VAS), the Health Utilities Index Mark 3 (HUI3), and standard gamble (SG) and time trade-off (TTO) techniques. RESULTS: The mean (SD) baseline HRQoL scores were as follows: MOS-HIV physical health summary score 41.70 (11.16), MOS-HIV mental health summary score 44.76 (11.38), EQ-5D 0.77 (0.19), HUI3 0.59 (0.32), EQ-5D VAS 65.94 (21.71), SG 0.75 (0.29), and TTO 0.80 (0.31). Correlations between MOS-HIV summary scores and EQ-5D, EQ-5D VAS, and HUI3 ranged from 0.60 to 0.70; the correlation between EQ-5D and HUI3 was 0.73; and the correlation between SG and TTO was 0.43. Preference-based HRQoL scores were related to physical, mental, social, and overall health as measured by MOS-HIV. Concomitant medication use, CD4 cell count, and HIV viral load were related to some instruments' scores. CONCLUSIONS: On average, preference-based HRQoL for treatment-experienced HIV patients was decreased relative to national norms but also highly variable. Health status and clinical variables were related to HRQoL.

KW - Adult

KW - Anti-HIV Agents/therapeutic use

KW - Canada

KW - Cross-Sectional Studies

KW - Female

KW - Great Britain

KW - HIV Infections/drug therapy/psychology

KW - Humans

KW - Male

KW - Middle Aged

KW - Quality of Life

KW - Questionnaires

KW - Socioeconomic Factors

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=64249151889&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31818ce6f3

DO - 10.1097/QAI.0b013e31818ce6f3

M3 - Article

VL - 50

SP - 27

EP - 36

JO - J Acquir Immune Defic Syndr

JF - J Acquir Immune Defic Syndr

IS - 1

ER -